Our latest podcasts feature the European Society of Cardiology (ESC) Congress held recently in Barcelona, Spain, and highlight our selection of trials, registry data and guideline updates that will change UK clinical practice.
Professor Keith Fox, University of Edinburgh, and Chairman of the ESC Programme Committee, discusses:
• in heart failure – PARADIGM-HF and CONFIRM-HF
• in coronary artery disease – SIGNIFY, ATLANTIC, CULPRIT, MITOCARE, COMPLETE and TASTE
• in arrhythmia – X-VERT and STICS
• and in lipid lowering – ODYSSEY and SOLID-TIMI 52
View Keith Fox interview now
This podcast has been made possible by unrestricted educational grants from Bayer Healthcare (Job code L.GB.10.2014.8412; Date of preparation October 2014) and Sanofi/Regeneron (Job code SAGB.CMR.14.10.0599b)
Dr Christopher Cannon, Harvard Clinical Research Institute, Boston, USA, discusses:
• The ODYSSEY programme, including ODYSSEY COMBO II
• Were there any adherence issues given that the PCSK9 monoclonal antibody therapies are injected subcutaneously?
• Current evidence on the danger of neurocognitive adverse effects
• Patient priorities for these treatments
View Christopher Cannon interview now
This podcast has been made possible by an unrestricted educational grant from Sanofi/Regeneron (Job code SAGB.CMR.14.10.0599a)
Professor Kausik Ray, St George’s Hospital, University of London, puts these studies into clinical perspective, and explains why the extent of LDL cholesterol lowering is key in the prevention of cardiovascular disease, rather than the means of LDL cholesterol lowering, using:
• Insights from genetic and observational studies
• Insights from clinical trials
• And considering whether very low LDL-C levels are safe
View Kausik Ray interview now
This podcast has been made possible by an unrestricted educational grant from Sanofi/Regeneron (Job code SAGB.CMR.14.10.0599c)
